Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: A pilot study

Article Abstract:

A study was conducted to determine if the variation in genes of pharmacological interest were associated with the pharmacokinetic and pharmacodynanic profile of indinavir (IDV), zidovudine (ZDV), and lamivudine. Results revealed that the novel relationships were identified among genetic variants in drug transporters and indinavir, lamivudine-triphosphate, and zidovudine-triphosphate concentrations.

Author: Schuetz, Erin, Fletcher, Courtney V., Anderson, Peter L., Aquilante, Christina L., Lamba, Jatinder
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2006
Analysis, Indinavir, Pharmacogenetics, Pharmacogenomics

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Risk factors for in utero and intrapartum transmission of HIV

Article Abstract:

A study is done to identify predictors of in utero and intrapartum HIV-1 transmission in infants born in the women and infants transmission study between 1990 and 2000. The result showed that there has been an increase in the proportion of infections transmitted in utero, while there has been significant declines in perinatal HIV-1 infection over time.

Author: Mofenson, Lynne, Landesman, Sheldon, Tuomala, Ruth E., Magder, Laurence S., Blattner, William A., Zorrilla, Carmen D., Paul, Mary E., LaRussa, Phil, Rich, Kenneth C.
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2005
Science & research, Research, Risk factors

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life

Article Abstract:

The safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in 26 infants during the first six weeks of life is described. It is found that nelfinavir is well tolerated by the infants, with few adverse events attributed to the drug.

Author: Mofenson, Lynne, Watts, Heather, Stek, Alice, Hughes, Michael, Bryson, Yvonne, Connor, James, Huang, Sharon, Capparelli, Edmund, Mirochnick, Mark, Acevedo, Midnela, Holland, Diane, Keller Margaret
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2005
Health aspects, Infants, Nelfinavir

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: HIV infection, Drug therapy, HIV infections, Dosage and administration, Zidovudine, Lamivudine, United States, HIV infection in children, Pediatric HIV infections
Similar abstracts:
  • Abstracts: Initiation of antiretroviral therapy during recent HIV-1 infection results in lower residual viral reservoirs
  • Abstracts: Genotypic resistance and immunologic outcomes among HIV-1 infected women with viral failure. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy
  • Abstracts: Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL)
  • Abstracts: Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial
  • Abstracts: Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. Progressive multifocal leukencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.